FDA 483 OBSERVATION · #366 OF 1,932 MOST-CITED

Procedures to meet core CTGP

FDA cited this observation 75 times across 70 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Human Tissue for Transplantation75
BY FISCAL YEAR
FY20263
FY202511
FY20242
FY20234
FY20227
FY20214
FY20204
FY201913
FY20188
FY201711
FY20168

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 2× the rate of the average FDA-cited firm (15.7% vs 7.8%), across 70 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

Procedures appropriate to meet core CGTP requirements for all steps that you perform in the manufacture of HCT/Ps were not followed.

RTI Surgical, Inc. · Alachua, Florida · Human Tissue for Transplantation · 2026-01-30

Procedures appropriate to meet core CGTP requirements for all steps that you perform in the manufacture of HCT/Ps were not established.

Isomedix Operations, Inc. · Libertyville, Illinois · Human Tissue for Transplantation · 2026-01-27

Procedures appropriate to meet core CGTP requirements for all steps that you perform in the manufacture of HCT/Ps were not followed.

Greater Delaware Valley Society of Transplant Surgeons · Philadelphia, Pennsylvania · Human Tissue for Transplantation · 2026-01-09

Procedures appropriate to meet core CGTP requirements for all steps that you perform in the manufacture of HCT/Ps were not followed.

Newton Implant Systems, Inc. · Vista, California · Human Tissue for Transplantation · 2025-08-18

Procedures appropriate to meet core CGTP requirements for all steps that you perform in the manufacture of HCT/Ps were not established, maintained and defined.

Solid MD Inc · Carrollton, Texas · Human Tissue for Transplantation · 2025-08-15

Procedures appropriate to meet core CGTP requirements for all steps that you perform in the manufacture of HCT/Ps were not established and maintained.

CTON Corporation · Torrance, California · Human Tissue for Transplantation · 2025-07-25

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality system →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →